Abstract Details

Title Natalizumab Discontinuation: Observational Study of University of Colorado Patients with Relapsing-Remitting Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 170

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Ngozi A. Nnunukwe, MD (University of North Carolina)	No disclosure on file
Teri Schreiner, MD, MPH, FAAN (University of Colorado/ Children's Hospital of Colorado)	The institution of Dr. Schreiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CDC. Dr. Schreiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Schreiner has received research support from Roche Genentech.
Jing Marantz	No disclosure on file

��ɫ��